Skip to content

The Influence of Desensitizing Agent on Postoperative Sensitivity in Posterior Composite Restoration

The Influence of Desensitizing Agent on Postoperative Sensitivity in Posterior Composite Restoration: A Randomized Controlled Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06113874
Enrollment
10
Registered
2023-11-02
Start date
2022-07-05
Completion date
2023-08-30
Last updated
2023-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dentin Hypersensitivity

Brief summary

This study aims to investigate the influence of desensitizing agents on reducing post-operative sensitivity in posterior composite.

Interventions

OTHERHurriseal desensitizer

Patients will receive Hurriseal desensitizing agent and universal bond and composite. Cavities will be restored with light-cured composite resin following the application of bonding agent.

Patients will receive Gluma desensitizing agent and universal bond and composite. Cavities will be restored with light-cured composite resin following the application of bonding agent.

Sponsors

Nourhan M.Aly
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Patients having active primary class I carious lesions on vital molar teeth either in the middle or the inner third of dentin in the three quadrants of each patients. * Teeth having a positive reaction to vitality test (cold test), no signs of pulp inflammation, or spontaneous pain before treatment. * Preoperative radiographic record of the carious lesions. * Buccolingual width is no more than half the inter-cuspal distance

Exclusion criteria

* Excessive tooth wear due to clenching or abnormal habits. * Patients with direct occlusal contact by antagonist cusp (traumatic occlusion). * Patients with periodontal or gingival disease. * Patients using analgesics and/or anti-inflammatory medicine.

Design outcomes

Primary

MeasureTime frameDescription
Hypersensitivity assessmentup to 12 monthsAir spray will be applied from a 2-mm distance on to the occlusal for 3 seconds. The severity of patients' pain/sensitivity will be recorded using (0-10) numerical rating scale. The score will be ranged from 0 (No pain) to 10 (maximum pain)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026